Equities researchers at StockNews.com started coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) in a note issued to investors on Tuesday. The firm set a “hold” rating on the medical research company’s stock.
Separately, BTIG Research upgraded Accelerate Diagnostics to a “strong-buy” rating in a report on Wednesday, December 11th.
View Our Latest Research Report on Accelerate Diagnostics
Accelerate Diagnostics Stock Performance
Insider Buying and Selling at Accelerate Diagnostics
In other Accelerate Diagnostics news, Director John Patience acquired 200,000 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The stock was acquired at an average cost of $1.57 per share, with a total value of $314,000.00. Following the purchase, the director now directly owns 653,224 shares in the company, valued at approximately $1,025,561.68. This trade represents a 44.13 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 43.60% of the stock is owned by company insiders.
Hedge Funds Weigh In On Accelerate Diagnostics
A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new position in Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned about 0.08% of Accelerate Diagnostics as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 17.14% of the company’s stock.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Featured Stories
- Five stocks we like better than Accelerate Diagnostics
- Election Stocks: How Elections Affect the Stock Market
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- How to Buy Cheap Stocks Step by Step
- 3 Steel Stocks Soaring After Tariff Announcements
- Quiet Period Expirations Explained
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.